

Células T con receptor quimérico de anticuerpos anti-HLA de clase I como terapia en el trasplante





Sergi Betriu Méndez

- Servei d'immunologia
- Hospital Clínic de Barcelona – IDIBAPS-FCRB




INTRODUCCION

Importancia de los anticuerpos DSA en trasplante




Antibody-mediated rejection




INTRODUCCION

Estructura de un CAR



Terapia CAR-T





OBJETIVOS

Desarrollar células T con receptor quimérico de anticuerpos anti-HLA de clase I (CHAR-Tc) que eliminen específicamente células B productoras de anticuerpos HLA de clase I donante-específico con la finalidad de obtener una terapia de desensibilización y/o tratamiento de ABMR a la carta.



METODOS Y RESULTADOS

Generación de la secuencia del receptor quimérico



METODOS Y RESULTADOS


Transducción de la secuencia del receptor en linfocitos T CD3+



METODOS Y RESULTADOS

Actividad citotóxica *in vitro*.

Cytotoxic effect




Identification, Isolation, and Culture of HLA-A2-Specific B Lymphocytes Using MHC Class I Tetramers¹

Arend Mulder,² Chantal Eijsink, Marrie J. Kardol, Marry E. I. Franke-van Dijk, Sjoerd H. van der Burg, Michel Kester, Ilias I. N. Doxiadis, and Frans H. J. Claas


METODOS Y RESULTADOS

Actividad citotóxica *in vitro*.

Cytotoxic effect





A





METODOS Y RESULTADOS

Citocinas *in vitro*



B





UT-Tc A2-CHAR-Tc



UT-Tc A2-CHAR-Tc




UT-Tc A2-CHAR-Tc



UT-Tc A2-CHAR-Tc

METODOS Y RESULTADOS


Citocinas *in vitro*



METODOS Y RESULTADOS




Citocinas *in vitro*

B



METODOS Y RESULTADOS

Actividad citotóxica *in vivo*.



CONCLUSIONES

- La tecnología CHAR puede ser usada para generar células T citotóxicas humanas funcionales que selectivamente eliminen células B productoras de anticuerpos anti-HLA de clase I
- La tecnología CHAR podrá usarse en protocolos de desensibilización e incluso como terapia ABMR.

¡Muchas gracias!

Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS

Fritz Diekmann
Jordi Rovira
Ainhoa García
Carolt Arana
Marina Matilla
Maria Jose Ramirez
Elisenda Banon
Marta Lazo
Beatriu Bayés
Josep M Campistol

Servei d'Immunologia, HCB

Eduard Palou
Manel Juan
Sergi Betriu
Ariadna Bartoló

Leiden University Medical Center

Frans H. Claas
Arend Mulder
Sebastian Heidt



L'Acadèmia
FUNDACIÓ ACADÈMIA DE CIÈNCIES MÈDIQUES
I DE LA SALUT DE CATALUNYA I DE BALEARNS

FUNDACIÓ
CLÍNIC
BARCELONA

IDIBAPS
Institut
D'investigacions
Biomèdiques
August Pi i Sunyer



UNIVERSITAT DE
BARCELONA